ArticleFrontiers in immunology2025
Influencing factor analysis and prediction model construction of dupilumab treatment adherence: a prospective cohort study in moderate-to-severe atopic dermatitis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of dupilumab in atopic dermatitis (AD) has been widely validated; however, systematic investigations into treatment adherence are lacking. Objective: To analyze clinical factors influencing dupilumab adherence in patients with moderate-to-severe AD and develop a multidimensional adherence prediction model to support precision management of biologic therapies. Methods: Using a single-center prospective cohort, a three-stage modeling approach was applied: (1) univariable Cox proportional hazards regression to identify potential predictors; (2) XGBoost modeling with SHAP method for feature importance ranking and dimensionality reduction; (3) multivariable Cox proportional hazards model for final prediction. Results: Univariable analysis indicated that treatment discontinuation was significantly associated with age, sex, combination therapy, baseline disease activity, and treatment response. Machine learning identified EASI/NRS and EASI-75/SLS-75 as key predictors of baseline disease activity and treatment response, respectively. The multivariable model confirmed independent predictive value for age, baseline EASI/NRS scores, and achievement of EASI-75/SLS-75. Conclusion: This study identified key determinants of dupilumab adherence and developed a predictive adherence model that offers personalized risk visualization via nomograms, providing an evidence-based tool for the precision management of AD biologic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.